GLPwatch
Wegovy for Alcohol use disorder
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for alcohol use disorder, and any use for this condition is off-label or investigational. Research in rats suggests semaglutide may reduce alcohol intake and relapse-like drinking.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Alcohol use disorder |
| Approval status | Investigational / off-label |
| Research papers | 16 |
Wegovy is not FDA-approved for alcohol use disorder; the research below reflects investigational or off-label study only.
Research on semaglutide for alcohol use disorder (16)
- The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.
- Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
- Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats.
- Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
- Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.
- Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
- Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.
- Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
- Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.
- Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.
- Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
- Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.
- Semaglutide: A New Medical Swiss Army Knife?
- Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.
- Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.